A Phase 1 Dose-escalation, Single-Center, Open-labeled Study to Evaluate the Safety and Tolerability of Human Induced Pluripotent Stem Cell-derived Human Forebrain Neural Progenitor Cell Injection (hNPC01) in Chronic Ischemic Stroke
Latest Information Update: 12 Mar 2024
At a glance
- Drugs HNPC 01 (Primary)
- Indications Ischaemic stroke
- Focus Adverse reactions
- Sponsors Hopstem Biotechnology
Most Recent Events
- 12 Mar 2024 New trial record